JP2023538522A5 - - Google Patents
Info
- Publication number
- JP2023538522A5 JP2023538522A5 JP2023507911A JP2023507911A JP2023538522A5 JP 2023538522 A5 JP2023538522 A5 JP 2023538522A5 JP 2023507911 A JP2023507911 A JP 2023507911A JP 2023507911 A JP2023507911 A JP 2023507911A JP 2023538522 A5 JP2023538522 A5 JP 2023538522A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062990P | 2020-08-07 | 2020-08-07 | |
| US63/062,990 | 2020-08-07 | ||
| US202163135946P | 2021-01-11 | 2021-01-11 | |
| US63/135,946 | 2021-01-11 | ||
| PCT/US2021/045008 WO2022032137A1 (en) | 2020-08-07 | 2021-08-06 | Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538522A JP2023538522A (ja) | 2023-09-08 |
| JPWO2022032137A5 JPWO2022032137A5 (https=) | 2024-08-09 |
| JP2023538522A5 true JP2023538522A5 (https=) | 2024-08-09 |
Family
ID=77543654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507911A Abandoned JP2023538522A (ja) | 2020-08-07 | 2021-08-06 | Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220072127A1 (https=) |
| EP (1) | EP4192446A1 (https=) |
| JP (1) | JP2023538522A (https=) |
| KR (1) | KR20230050379A (https=) |
| CN (1) | CN116096365A (https=) |
| AU (1) | AU2021320417A1 (https=) |
| BR (1) | BR112023002085A2 (https=) |
| CA (1) | CA3188213A1 (https=) |
| IL (1) | IL300429A (https=) |
| MX (1) | MX2023001481A (https=) |
| WO (1) | WO2022032137A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| KR20240167914A (ko) * | 2022-04-04 | 2024-11-28 | 이노자임 파마, 인코포레이티드 | Enpp1 결핍증 및 abcc6 결핍증의 치료 |
| WO2025185644A1 (zh) * | 2024-03-05 | 2025-09-12 | 江苏恒瑞医药股份有限公司 | 抗angptl3抗体治疗高血脂症的用途及方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| RU2723018C2 (ru) * | 2014-07-16 | 2020-06-08 | Санофи Байотекнолоджи | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию |
| PL3169353T3 (pl) * | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
| JP7541810B2 (ja) * | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| KR20180132843A (ko) * | 2016-04-08 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법 |
| IL293308B2 (en) * | 2016-04-28 | 2024-12-01 | Regeneron Pharma | Methods for treating patients with familial hypercholesterolemia |
-
2021
- 2021-08-06 AU AU2021320417A patent/AU2021320417A1/en not_active Abandoned
- 2021-08-06 CA CA3188213A patent/CA3188213A1/en active Pending
- 2021-08-06 MX MX2023001481A patent/MX2023001481A/es unknown
- 2021-08-06 JP JP2023507911A patent/JP2023538522A/ja not_active Abandoned
- 2021-08-06 IL IL300429A patent/IL300429A/en unknown
- 2021-08-06 US US17/396,399 patent/US20220072127A1/en not_active Abandoned
- 2021-08-06 WO PCT/US2021/045008 patent/WO2022032137A1/en not_active Ceased
- 2021-08-06 EP EP21762903.9A patent/EP4192446A1/en not_active Withdrawn
- 2021-08-06 BR BR112023002085A patent/BR112023002085A2/pt unknown
- 2021-08-06 KR KR1020237007956A patent/KR20230050379A/ko active Pending
- 2021-08-06 CN CN202180058786.0A patent/CN116096365A/zh not_active Withdrawn
-
2023
- 2023-12-12 US US18/537,578 patent/US20240197870A1/en not_active Abandoned